Search

everythinglearnresearchcommunity

for

Search:↓

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

Transcutaneous vaccination using nanoparticles can enhance immune responses and reduce basal cell carcinomas.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

Blocking interferon-gamma helps prevent and treat hair loss in Alopecia Areata.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

Alopecia areata is linked to thyroid autoimmunity but not type 1 diabetes.

Alopecia areata is caused by an immune response, and targeting immune cells might help treat it.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

ILC1-like cells can cause alopecia areata by affecting hair follicles.

Higher CD8+ T cell levels are linked to Alopecia areata in Iraqi patients.

Higher levels of certain immune cells in hair follicles may contribute to alopecia areata.

Malt1 protease is essential for regulatory T cell function and could be targeted to boost antitumor immunity.

Topical immunotherapy for alopecia areata may work by creating immune cell clusters in the skin.

Memory T cells in the skin balance staying put and moving into the blood, clustering around hair follicles, and increasing in number after infection.

Tph cells are linked to the severity of systemic lupus erythematosus.

Modified superoxide dismutase may trigger an autoimmune response in alopecia areata.

The study suggests that a specific type of immune cell, memory-like NK cells, may increase during active hair loss in Alopecia areata.

Alopecia areata may be caused by the immune system attacking hair follicles.

Memory regulatory T cells need IL-7, not IL-2, to stay in peripheral tissues.

Relatives of lupus patients show signs of immune system activity but not full-blown lupus.

Anti-TNF therapy can cause a rare hair loss condition similar to alopecia areata.

Arg1+ macrophages may play a role in Alopecia Areata, offering new treatment targets.

Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.

T-cell reconstitution after thymus transplantation can cause hair whitening and loss.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

CD8+ T cells play a key role in graft-versus-host disease in certain mice models.

Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.

Fetal skin has unique immune cells different from adult skin.

Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.

Immune cell-targeting biologics show potential for treating alopecia areata but need better-targeted therapies.